The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo
Pharmacological Research · 2023-10 · 196 · 106926
DOI: 10.1016/j.phrs.2023.106926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacological Research, 2023-10. Verfasst von Yuheng Pang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Doxorubicin, Vorinostat, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical University, Harbin,…
- Department of Breast Surgery, Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, PR China.
- College of Pharmaceutical Sciences, Capital Medical University, Beijing, PR China.
- Pathology Teaching and Research Section, Basic Medical College of Harbin Medical University, Harbin, Heilongjiang, PR China; NHC Key Laboratory of Cell Transplantation, The First Affiliated Hospital of Harbin Medical Un…
- College of Pharmaceutical Sciences, Capital Medical University, Beijing, PR China. Electronic address: wangyuji@ccmu.edu.cn.
- Beijing Institute of Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing, PR China. Electronic address: wangwenjing85321@ccmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Pang, Y., Shi, R., Chan, L., Lu, Y., Zhu, D., Liu, T., Yan, M., Wang, Y., & Wang, W. (2023). The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharmacological Research, 196, 106926. https://doi.org/10.1016/j.phrs.2023.106926
Vancouver
Pang Y, Shi R, Chan L, Lu Y, Zhu D, Liu T, et al. The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo. Pharmacological Research. 2023;196:106926. doi:10.1016/j.phrs.2023.106926
BibTeX
@article{Pang2023,
author = {Pang, Yuheng and Shi, Runze and Chan, Liujia and Lu, Yu and Zhu, Di and Liu, Tong and Yan, Meisi and Wang, Yuji and Wang, Wenjing},
title = {The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo},
journal = {Pharmacological Research},
year = {2023},
volume = {196},
pages = {106926},
doi = {10.1016/j.phrs.2023.106926}
}
EUVIMED